There is considerable interindividual variability in the response to antiplatelet and
anticoagulant therapies, and this variation may be attributable to genetic variants. There has …

Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an
intricate interplay of environmental and genetic factors. Genes not only influence …

Circulatory disease accounts for fifteen million deaths each year, of which stroke accounts
for four and a half million-with an estimated nine million stroke survivors annually. The …

Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances,
primarily using the genome-wide association study approach, are transforming what we …

Genetic variations have been shown to influence drug metabolism, risk of adverse drug
events, and pharmacodynamic responses for many drugs routinely used to treat patients …

Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as
we learn more about the individual genetic variations that contribute to the drugs' efficacy …

The field of medical and population genetics in stroke is moving at a rapid pace and has led
to unanticipated opportunities for discovery and clinical applications. Genome-wide …

The late 20th and early 21st centuries have seen a reduction in stroke risk resulting from
lifestyle changes such as widespread smoking cessation and more regular exercise …

Introduction Stroke is one of the main causes of death and disability worldwide.
Nevertheless, despite the global burden of this disease, our understanding is limited and …

Antiplatelet drugs are widely utilized in the setting of primary stroke prevention, secondary
stroke prevention, and neuroendovascular device-related stroke prevention. These …